As with other dipeptide-linked auristatin-based immunoconjugates [61–63], preliminary results of a phase II trial of the anti-CD22-MMAE immunoconjugate pinatuzumab vedotin in combination with rituximab in patients with relapsed/refractory non-Hodgkin lymphoma reported on significant payload-related systemic toxicities including neutropenia and peripheral neuropathy [64]. This evidence concerns the gene CD22 and non-Hodgkin lymphoma.